Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AmBisome plus isavuconazole vs AmBisome in pulmonary mucormycosis
ChiCTR2500095746Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in mucormycosis comparing AmBisome plus isavuconazole with AmBisome monotherapy (2 arms). Primary endpoint: Overall favourable response at day 28. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
amphotericin bisavuconazole
03
Conditions
mucormycosis
Beyond the preview
Go deeper on ChiCTR2500095746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095746.